In conclusion, consistent with findings from other trials of T-DXd in gastric cancers,14,21,24 T-DXd showed durable clinical benefit, with no new safety signals identified, in patients from China with previously treated HER2+ advanced gastric cancer or GEJ adenocarcinoma. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.